Strong Buy Rated Stocks
BBOT is part of our Strong Buy Rated Stocks screen, indicating it has a strong buy ratings from analysts and supporting business quality.
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) Stock Price & Overview
NASDAQ:BBOT • US1079241022
Current stock price
8.91 USD
-0.12 (-1.33%)
At close:
8.91 USD
0 (0%)
After Hours:
The current stock price of BBOT is 8.91 USD. Today BBOT is down by -1.33%. In the past month the price decreased by -9.91%.
BBOT Key Statistics
1-Month Range8.51 - 11.02
Current BBOT stock price positioned within its 1-month range.
- Market Cap
- 713.067M
- P/E
- 44.55
- Fwd P/E
- N/A
- EPS (TTM)
- 0.20
- Dividend Yield
- N/A
BBOT Stock Performance
Today
-1.33%
1 Week
-3.47%
1 Month
-9.91%
3 Months
-27.50%
Longer-term
6 Months -27.91%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
BBOT Stock Chart
BBOT Stock Screens
BBOT currently appears in the following ChartMill screener lists.
BBOT Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to BBOT.
Chartmill TA Rating
Chartmill Setup Rating
BBOT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BBOT. The financial health of BBOT is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BBOT Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 5, 2026
PeriodQ4 / 2025
EPS Reported-$0.49
Revenue Reported
EPS Surprise 7.11%
Revenue Surprise %
BBOT Forecast & Estimates
15 analysts have analysed BBOT and the average price target is 25.88 USD. This implies a price increase of 190.49% is expected in the next year compared to the current price of 8.91.
Analysts
Analysts86.67
Price Target25.88 (190.46%)
EPS Next Y-1034.53%
Revenue Next YearN/A
BBOT Groups
Sector & Classification
BBOT Financial Highlights
Over the last trailing twelve months BBOT reported a non-GAAP Earnings per Share(EPS) of 0.2. The EPS increased by 17.4% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)4.72M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 2.39% | ||
| ROE | 2.49% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-58.45%
Sales Q2Q%N/A
EPS 1Y (TTM)17.4%
Revenue 1Y (TTM)N/A
BBOT Ownership
Ownership
Inst Owners69.87%
Shares80.03M
Float58.36M
Ins Owners0.11%
Short Float %3.87%
Short Ratio9.75
BBOT Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BBOT
Company Profile
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
Company Info
IPO: 2024-02-09
BRIDGEBIO ONCOLOGY THERAPEUT
256 E. Grand Avenue, Suite 104
South San Francisco CALIFORNIA US
Employees: 0
Phone: 18577020377
BRIDGEBIO ONCOLOGY THERAPEUT / BBOT FAQ
What does BBOT do?
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
What is the current price of BBOT stock?
The current stock price of BBOT is 8.91 USD. The price decreased by -1.33% in the last trading session.
What is the dividend status of BRIDGEBIO ONCOLOGY THERAPEUT?
BBOT does not pay a dividend.
How is the ChartMill rating for BRIDGEBIO ONCOLOGY THERAPEUT?
BBOT has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) based on its PE ratio?
The PE ratio for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 44.55. This is based on the reported non-GAAP earnings per share of 0.2 and the current share price of 8.91 USD.
When does BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) report earnings?
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) will report earnings on 2026-05-07.
What is the Short Interest ratio of BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) stock?
The outstanding short interest for BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) is 3.87% of its float.